Back to top

Analyst Blog

AstraZeneca (AZN - Analyst Report) recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for two of its candidates – olaparib and naloxegol.

AstraZeneca is looking to get olaparib approved as a maintenance therapy in BRCA mutated relapsed serous ovarian cancer patients, who have shown response to platinum-based chemotherapy in the EU.

The MAA for olaparib was submitted on the basis of a phase II study. The phase II study compared the efficacy and safety of olaparib versus placebo in patients suffering from platinum-sensitive, relapsed, high grade serous ovarian cancer. The patients had already been treated with two or more platinum-based regimens and exhibited a partial or complete response to the last platinum-based treatment regimen. A subgroup analysis revealed that olaparib significantly improved progression-free survival as compared to placebo.

Meanwhile, AstraZeneca is also seeking to market Naloxegol in the EU for the treatment of opioid-induced constipation in adults.

The MAA for Naloxegol was submitted on the basis of encouraging data from the phase III KODIAC program. AstraZeneca had licensed the candidate from Nektar Therapeutics (NKTR - Analyst Report) in Sep 2009. The acceptance of MAA by the EMA triggered a $25 million milestone payment from AstraZeneca to Nektar Therapeutics.

AstraZeneca’s pipeline is currently under severe pressure with revenues plunging due to generic competition faced by several key drugs including Seroquel. We believe that approval of these candidates would provide a much needed boost to AstraZeneca’s revenues.

AstraZeneca carries a Zacks Rank #3 (Hold). Currently, companies like Roche (RHHBY - Analyst Report) and Actelion Ltd. (ALIOF) look well-positioned with both being Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%